Estrella Immunopharma, Inc. (ESLA) Stock Score, Valuation & Financial Research

Estrella Immunopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ESLA

Estrella Immunopharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.47. These figures are a research snapshot, not a buy or sell recommendation.

What Estrella Immunopharma, Inc. does

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Estrella Immunopharma is a clinical-stage biopharmaceutical company that has not yet generated revenue from product sales. Its business model relies on research and development of T-cell therapies, funded through capital raises, while outsourcing significant operational and research tasks to Eureka Therapeutics under a services agreement.

Products and services

  • Clinical-stage T-cell therapy candidates including EB103 (targeting CD19) and EB104 (dual-targeting CD19/CD22) for cancers and autoimmune diseases.

Suppliers, materials and equipment

  • Eureka Therapeutics, Inc. — Provides research and development services and manages operational tasks for clinical trials. Source

Business relationships and partnerships

  • Eureka Therapeutics, Inc. — Strategic partner providing research and development services, clinical trial management, and exclusive technology licenses. Source

Business strengths to evaluate

  • Exclusive licenses from Eureka Therapeutics for proprietary ARTEMIS-platform T-cell therapy technology. Source

Business risks and research considerations

  • Substantial need for additional financing to fund future operations and clinical development. Source
  • Heavy reliance on Eureka Therapeutics for research, development, and operational management. Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ESLA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.47
Market capitalization:
19.97M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.01M
Free cash flow:
USD -1.79M
Cash:
USD 146.67K
Total debt:
USD 0.00
EPS:
USD -0.25

What stands out

  • Free cash flow is USD -1.79M, negative for the stored period.
  • The balance sheet shows USD 146.67K of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 146.67K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ESLA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ESLA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ESLA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ESLA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ESLA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research ESLA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.